Elyse Page
4PUBLICATIONS
11CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|Jun 07, 2024
Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy.Laura N Eadie, Elias Lagonik, Elyse C Page
|Jan 13, 2022
Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia.Paniz Tavakoli Shirazi, Laura N Eadie, Susan L Heatley
|Dec 03, 2021
HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort.Elyse C Page, Susan L Heatley, Laura N Eadie
|Aug 11, 2021
Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia.Charlotte E J Downes, Barbara J McClure, John B Bruning
Pageof 1
Frequent Collaborators
4 joint publications
Deborah L White
3 joint publications
Susan L Heatley
3 joint publications
Barbara J McClure
1 joint publications
Sofia Omari
1 joint publications
Paniz Tavakoli Shirazi
1 joint publications
Laura N Eadie
1 joint publications
Elias Lagonik
1 joint publications
David T Yeung
1 joint publications
Charlotte E J Downes
1 joint publications
John B Bruning
